METAVIA INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
METAVIA INC. (MTVA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -12.30% for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-31.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2022-03-31
- METAVIA INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was -12.30%.
- METAVIA INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2019 was -15.60%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2020-12-31 | -12.30% 10-K · filed 2022-03-31 |
| 2019-12-31 | -15.60% 10-K · filed 2021-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |